tumors (Novus Biologicals)
Novus Biologicals is a verified supplier 
Novus Biologicals manufactures this product 
93
Structured Review
Novus Biologicals
tumors
Tumors, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/maxarray%E2%84%A2+human+prostate+microarray+slides/Human+Prostate+Tissue+MicroArray+(Cancer)/pmc04358924-88-14-18
Average 93 stars, based on 24 article reviews
Tumors, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/maxarray%E2%84%A2+human+prostate+microarray+slides/Human+Prostate+Tissue+MicroArray+(Cancer)/pmc04358924-88-14-18
Average 93 stars, based on 24 article reviews
tumors - by Bioz Stars,
2026-09
93/100 stars
Images
Related Articles
Recombinant:Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis. Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Microarray:Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis. Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Immunohistochemistry:Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis. Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Immunofluorescence:Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis. Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Imaging:Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis. Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Staining:Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis. Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from |